Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function

Post by: Geert in Immunic Press Release
Immunic, Inc. Announces Dosing of…
read more
20 Aug 2020
0

Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Post by: Geert in Immunic Press Release
Immunic, Inc. Announces Closing of…
read more
20 Aug 2020
0

Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock

Post by: Geert in Immunic Press Release
Immunic, Inc. Announces Pricing of…
read more
20 Aug 2020
0

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19

Post by: Geert in Immunic Press Release
Immunic, Inc. Announces First Patients…
read more
15 Jun 2020
0

Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock

Post by: Geert in Immunic Press Release
Immunic, Inc. Announces Pricing of…
read more
12 Jun 2020
0

Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients

Post by: Geert in Immunic Press Release
Immunic, Inc. Receives First Regulatory…
read more
14 May 2020
0

Immunic, Inc. Announces Pricing of $15 Million Financing

Post by: Geert in Immunic Press Release
Immunic, Inc. Announces Pricing of…
read more
24 Apr 2020
0

Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients

Post by: Geert in Immunic Press Release
Immunic, Inc. Reports that IMU-838,…
read more
22 Apr 2020
0

Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson

Post by: Geert in Immunic Press Release
Immunic, Inc. Expands Board of…
read more
16 Oct 2019
0

Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

Post by: Geert in Immunic Press Release
Immunic, Inc. Announces Completion of…
read more
11 Oct 2019
0